Aarhus University Seal / Aarhus Universitets segl

Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information. / Khialani, Deeksha; Jones, Mary Elizabeth; Szépligeti, Szimonetta Komjáthiné; Ording, Anne Gulbech; Ehrenstein, Vera; Petersen, Irene; van Hylckama Vlieg, Astrid.

In: Contraception: X, Vol. 2, 100018, 2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Khialani, Deeksha ; Jones, Mary Elizabeth ; Szépligeti, Szimonetta Komjáthiné ; Ording, Anne Gulbech ; Ehrenstein, Vera ; Petersen, Irene ; van Hylckama Vlieg, Astrid. / Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information. In: Contraception: X. 2020 ; Vol. 2.

Bibtex

@article{6217e96df26e4e5184ebcc17e2187672,
title = "Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information",
abstract = "Objectives: We investigated combined hormonal contraceptives (CHC) prescribing patterns (focusing on combined oral contraceptives; COC) in three countries (Netherlands, Denmark, United Kingdom) in a time period preceding and in a time period following the European Commission's decision to update product information, and we estimated changes in incidence of venous thromboembolism (VTE) between the two periods. Study design: We conducted a drug utilization analysis and a cohort study using routinely collected data. We calculated number, proportion and incidence rate of new users, switchers, and stoppers of COC in both time periods. VTE incidence was calculated in new users of COC and in all women aged 18–49 years. Results: In all countries, the largest proportion (> 75%) of new users used COC containing levonorgestrel, norethisterone, or norgestimate, (i.e., indicated by European Medicines Agency (EMA) as the safest preparations) in both time periods. Switching did not demonstrate a clear pattern towards these types of COC and distribution of stoppers was similar in both time periods. While the proportion of new users initiating COC containing levonorgestrel, norethisterone, or norgestimate increased slightly, this did not translate to a decrease in the overall VTE incidence. Conclusion: All three countries had the greatest proportion of women initiating a COC containing levonorgestrel, norethisterone, or norgestimate, and this proportion increased in the period after the European Commission decision albeit the increase was small due to the high percentage of use before the decision. This did not translate into a measureable change in the incidence of VTE. Implications: Both before and after the European Commission's decision, the largest proportion of new users started with combined oral contraceptives containing levonorgestrel, norethisterone, or norgestimate. Earlier studies had already indicated an increased risk of VTE associated with COC containing other progestogens compared with these preparations, so it is possible that physicians were already preferentially prescribing COC containing levonorgestrel, norethisterone, or norgestimate to new users.",
keywords = "Combined oral contraceptives, Prescription patterns, Risk, Venous thromboembolism",
author = "Deeksha Khialani and Jones, {Mary Elizabeth} and Sz{\'e}pligeti, {Szimonetta Komj{\'a}thin{\'e}} and Ording, {Anne Gulbech} and Vera Ehrenstein and Irene Petersen and {van Hylckama Vlieg}, Astrid",
year = "2020",
doi = "10.1016/j.conx.2020.100018",
language = "English",
volume = "2",
journal = "Contraception: X",
issn = "2590-1516",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information

AU - Khialani, Deeksha

AU - Jones, Mary Elizabeth

AU - Szépligeti, Szimonetta Komjáthiné

AU - Ording, Anne Gulbech

AU - Ehrenstein, Vera

AU - Petersen, Irene

AU - van Hylckama Vlieg, Astrid

PY - 2020

Y1 - 2020

N2 - Objectives: We investigated combined hormonal contraceptives (CHC) prescribing patterns (focusing on combined oral contraceptives; COC) in three countries (Netherlands, Denmark, United Kingdom) in a time period preceding and in a time period following the European Commission's decision to update product information, and we estimated changes in incidence of venous thromboembolism (VTE) between the two periods. Study design: We conducted a drug utilization analysis and a cohort study using routinely collected data. We calculated number, proportion and incidence rate of new users, switchers, and stoppers of COC in both time periods. VTE incidence was calculated in new users of COC and in all women aged 18–49 years. Results: In all countries, the largest proportion (> 75%) of new users used COC containing levonorgestrel, norethisterone, or norgestimate, (i.e., indicated by European Medicines Agency (EMA) as the safest preparations) in both time periods. Switching did not demonstrate a clear pattern towards these types of COC and distribution of stoppers was similar in both time periods. While the proportion of new users initiating COC containing levonorgestrel, norethisterone, or norgestimate increased slightly, this did not translate to a decrease in the overall VTE incidence. Conclusion: All three countries had the greatest proportion of women initiating a COC containing levonorgestrel, norethisterone, or norgestimate, and this proportion increased in the period after the European Commission decision albeit the increase was small due to the high percentage of use before the decision. This did not translate into a measureable change in the incidence of VTE. Implications: Both before and after the European Commission's decision, the largest proportion of new users started with combined oral contraceptives containing levonorgestrel, norethisterone, or norgestimate. Earlier studies had already indicated an increased risk of VTE associated with COC containing other progestogens compared with these preparations, so it is possible that physicians were already preferentially prescribing COC containing levonorgestrel, norethisterone, or norgestimate to new users.

AB - Objectives: We investigated combined hormonal contraceptives (CHC) prescribing patterns (focusing on combined oral contraceptives; COC) in three countries (Netherlands, Denmark, United Kingdom) in a time period preceding and in a time period following the European Commission's decision to update product information, and we estimated changes in incidence of venous thromboembolism (VTE) between the two periods. Study design: We conducted a drug utilization analysis and a cohort study using routinely collected data. We calculated number, proportion and incidence rate of new users, switchers, and stoppers of COC in both time periods. VTE incidence was calculated in new users of COC and in all women aged 18–49 years. Results: In all countries, the largest proportion (> 75%) of new users used COC containing levonorgestrel, norethisterone, or norgestimate, (i.e., indicated by European Medicines Agency (EMA) as the safest preparations) in both time periods. Switching did not demonstrate a clear pattern towards these types of COC and distribution of stoppers was similar in both time periods. While the proportion of new users initiating COC containing levonorgestrel, norethisterone, or norgestimate increased slightly, this did not translate to a decrease in the overall VTE incidence. Conclusion: All three countries had the greatest proportion of women initiating a COC containing levonorgestrel, norethisterone, or norgestimate, and this proportion increased in the period after the European Commission decision albeit the increase was small due to the high percentage of use before the decision. This did not translate into a measureable change in the incidence of VTE. Implications: Both before and after the European Commission's decision, the largest proportion of new users started with combined oral contraceptives containing levonorgestrel, norethisterone, or norgestimate. Earlier studies had already indicated an increased risk of VTE associated with COC containing other progestogens compared with these preparations, so it is possible that physicians were already preferentially prescribing COC containing levonorgestrel, norethisterone, or norgestimate to new users.

KW - Combined oral contraceptives

KW - Prescription patterns

KW - Risk

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85078793638&partnerID=8YFLogxK

U2 - 10.1016/j.conx.2020.100018

DO - 10.1016/j.conx.2020.100018

M3 - Journal article

C2 - 32550533

AN - SCOPUS:85078793638

VL - 2

JO - Contraception: X

JF - Contraception: X

SN - 2590-1516

M1 - 100018

ER -